PMID- 11222671
OWN - NLM
STAT- MEDLINE
DCOM- 20010405
LR  - 20191023
IS  - 1529-2401 (Electronic)
IS  - 0270-6474 (Print)
IS  - 0270-6474 (Linking)
VI  - 21
IP  - 5
DP  - 2001 Mar 1
TI  - Previous exposure to amphetamine enhances the subsequent locomotor response to a 
      D1 dopamine receptor agonist when glutamate reuptake is inhibited.
PG  - RC133
AB  - The role of nucleus accumbens (NAcc) glutamate (GLU) and D(1) dopamine (DA) 
      receptor activation in the expression of locomotor sensitization to amphetamine 
      (AMPH) was investigated in rats. Rats were preexposed to either AMPH or saline, 
      and 2 weeks later their locomotion was assessed after a microinjection into the 
      NAcc of the selective glutamate reuptake blocker 
      l-trans-pyrrolidine-2,4-dicarboxylic acid (PDC) (10 nmol per side), the D(1)-like 
      DA receptor agonists SKF82958 (2.4 nmol per side) and SKF38393 (3.1 nmol per 
      side), the D(2)-like DA receptor agonist quinelorane (3.1 nmol per side), or AMPH 
      (6.8 nmol per side). All compounds other than quinelorane increased locomotion 
      when infused into the NAcc. Only AMPH, however, produced enhanced locomotion in 
      AMPH relative to saline-preexposed rats. When additional rats were tested after 
      NAcc infusions of PDC together with either SKF82958 or quinelorane, enhanced 
      locomotion was observed in AMPH relative to saline-preexposed rats after NAcc PDC 
      + SKF82958. These results suggest that in the NAcc, increased GLU 
      neurotransmission and activation of D(1) DA receptors, neither of which is by 
      itself sufficient, together contribute to the expression of locomotor 
      sensitization by AMPH. They stress, with other findings, the importance of GLU-DA 
      interactions in the NAcc not only in the generation of acute stimulant drug 
      effects but in sensitized responding to these drugs as well.
FAU - Kim, J H
AU  - Kim JH
AD  - Department of Psychiatry, The University of Chicago, Chicago, Illinois 60637, 
      USA.
FAU - Perugini, M
AU  - Perugini M
FAU - Austin, J D
AU  - Austin JD
FAU - Vezina, P
AU  - Vezina P
LA  - eng
GR  - DA-09860/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Neurosci
JT  - The Journal of neuroscience : the official journal of the Society for 
      Neuroscience
JID - 8102140
RN  - 0 (Benzazepines)
RN  - 0 (Central Nervous System Stimulants)
RN  - 0 (Dicarboxylic Acids)
RN  - 0 (Dopamine Agonists)
RN  - 0 (Excitatory Amino Acid Agents)
RN  - 0 (Neurotransmitter Uptake Inhibitors)
RN  - 0 (Pyrrolidines)
RN  - 0 (Quinolines)
RN  - 0 (Receptors, Dopamine D1)
RN  - 0 (Receptors, Dopamine D2)
RN  - 3KX376GY7L (Glutamic Acid)
RN  - 67287-49-4 (2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine)
RN  - 80751-65-1 (SK&F 82958)
RN  - 99319-03-6 (pyrrolidine-2,4-dicarboxylic acid)
RN  - CK833KGX7E (Amphetamine)
RN  - Z0X4VT3Y1Q (quinelorane)
SB  - IM
MH  - 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/administration & 
      dosage
MH  - Amphetamine/*administration & dosage
MH  - Animals
MH  - Benzazepines/administration & dosage
MH  - Central Nervous System Stimulants/administration & dosage
MH  - Dicarboxylic Acids/administration & dosage
MH  - Dopamine Agonists/*administration & dosage
MH  - Drug Administration Schedule
MH  - Drug Synergism
MH  - Excitatory Amino Acid Agents/*administration & dosage
MH  - Glutamic Acid/metabolism
MH  - Male
MH  - Microinjections
MH  - Motor Activity/*drug effects
MH  - Neurotransmitter Uptake Inhibitors/administration & dosage
MH  - Nucleus Accumbens/drug effects/metabolism
MH  - Pyrrolidines/administration & dosage
MH  - Quinolines/administration & dosage
MH  - Rats
MH  - Receptors, Dopamine D1/*agonists
MH  - Receptors, Dopamine D2/agonists
MH  - Time
PMC - PMC6762943
EDAT- 2001/02/27 10:00
MHDA- 2001/04/06 10:01
PMCR- 2001/09/01
CRDT- 2001/02/27 10:00
PHST- 2001/02/27 10:00 [pubmed]
PHST- 2001/04/06 10:01 [medline]
PHST- 2001/02/27 10:00 [entrez]
PHST- 2001/09/01 00:00 [pmc-release]
AID - 20015056 [pii]
AID - 5056 [pii]
AID - 10.1523/JNEUROSCI.21-05-j0003.2001 [doi]
PST - ppublish
SO  - J Neurosci. 2001 Mar 1;21(5):RC133. doi: 10.1523/JNEUROSCI.21-05-j0003.2001.